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Abstract
Background: Decisions concerning malaria treatment depend on species identification causing
disease. Microscopy is most frequently used, but at low parasitaemia (<20 parasites/μl) the
technique becomes less sensitive and time consuming. Rapid diagnostic tests based on Plasmodium
antigen detection do often not allow for species discrimination as microscopy does, but also
become insensitive at <100 parasites/μl.
Methods: This paper reports the development of a sensitive and specific real-time Quantitative
Nucleic Acid Sequence Based Amplification (real-time QT-NASBA) assays, based on the small-
subunit 18S rRNA gene, to identify the four human Plasmodium species.
Results: The lower detection limit of the assay is 100 – 1000 molecules in vitro RNA for all species,
which corresponds to 0.01 – 0.1 parasite per diagnostic sample (i.e. 50 μl of processed blood). The
real-time QT-NASBA was further evaluated using 79 clinical samples from malaria patients: i.e. 11
Plasmodium. falciparum, 37 Plasmodium vivax, seven Plasmodium malariae, four Plasmodium ovale and
20 mixed infections. The initial diagnosis of 69 out of the 79 samples was confirmed with the
developed real-time QT-NASBA. Re-analysis of seven available original slides resolved five
mismatches. Three of those were initially identified as P. malariae mono-infection, but after re-
reading the slides P. falciparum was found, confirming the real-time QT-NASBA result. The other
two slides were of poor quality not allowing true species identification. The remaining five
discordant results could not be explained by microscopy, but may be due to extreme low numbers
of parasites present in the samples. In addition, 12 Plasmodium berghei isolates from mice and 20
blood samples from healthy donors did not show any reaction in the assay.
Conclusion: Real-time QT-NASBA is a very sensitive and specific technique with a detection limit
of 0.1 Plasmodium parasite per diagnostic sample (50 μl of blood) and can be used for the detection,
identification and quantitative measurement of low parasitaemia of Plasmodium species, thus making
it an effective tool for diagnostic purposes and useful for epidemiological and drug studies.
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Background
Malaria is one of the leading infectious diseases in the
world, with 300–500 million clinical cases and 1–3 mil-
lion deaths each year [1]. Traditionally diagnosis of
malaria is based on microscopic detection of Plasmodium
parasites in Giemsa-stained blood slides. In recent dec-
ades, antigen detection assays and molecular detection
assays were introduced as alternatives to microscopy [2].
Antigen detection assays are mainly aimed at the identifi-
cation of Plasmodium falciparum. Only very few assays are
able to identify infections caused by other human Plasmo-
dium species [2,3]. Furthermore, the sensitivity and specif-
icity of these tests is low and parasite quantification is not
possible [3,4]. The application of molecular techniques
circumvents the limitations of conventional malaria diag-
nosis. PCR based assays are sensitive and can be converted
to a quantitative format if SYBR green or molecular probes
(e.g. a Taqman probe or a molecular beacon) are used in
real time assays [5-7]. Alternatively, Real-time Quantita-
tive Nucleic Acid Sequence Based Amplification (real-time
QT-NASBA) technology can be applied, which has some
advantages above real-time PCR assays. The real-time QT-
NASBA assay is simple and fast compared to real-time
PCR assays that can take up to four hours compared to 60
minutes in the case of NASBA [8,9]. Furthermore, real-
time QT-NASBA detects ribosomal RNA of which more
copies are present per genome in a parasite than the cor-
responding DNA on which PCR is based. This makes
NASBA a very sensitive diagnostic assay. Moreover,
NASBA is based on an isothermal reaction at 41 degrees
that does not require a DNA denaturing step hereby pre-
venting amplification of genomic DNA in case of contam-
ination [8]. Real-time QT-NASBA, using a molecular
beacon as detection probe, has been developed for P. fal-
ciparum and has shown to be very sensitive with a detec-
tion limit of 20 parasites/ml [9]. Detection of the other
parasites causing human malaria, i.e. Plasmodium vivax,
Plasmodium malariae and Plasmodium ovale, is of clinical
importance in order to decide on appropriate treatment.
This paper describes the development of a real-time QT-
NASBA for the detection, identification and quantifica-
tion of these Plasmodium species.
Methods
Primer/probe selection and in vitro RNA production
Generic  Plasmodium  forward (5'-TCAGATACCGTCG-
TAATCTTA-3') and reverse (5'-TTCGCGCAAGCA-
GAAAGTT-3') primers were used to amplify a 180 bp
region of P. vivax, P. ovale and P. malariae 18S rRNA gene
by PCR as previously described [10]. The amplified frag-
ments were cloned into plasmid pCR2 in Escherichia coli
INValphaF (Invitrogen, Carlsbad, California USA). Next,
in vitro RNA was produced with the transcription kit SP6/
T7 (Roche, Mannheim, Germany) and the cloned frag-
ment was sequenced (Base Clear, Leiden, The Nether-
lands). Production of P. falciparum 18S rRNA based in vitro
RNA was performed previously [10]. Primers were
selected on the basis of the DNA sequences of the three
species (Figure 1). Homology of these sequences with
published sequences and specificity of primers was ana-
lysed with the BLAST database for homology search [15].
The NASBA forward primers were chosen on their specifi-
city for the targeted species. P. falciparum: 5'GTCATCTT-
TCGACGTGACTT-3';  P. vivax: 5'-
TTTCTCTTCGGAGTTTATTC-3'; P. ovale: 5'-CGACATTGT-
CATTCCATTTAC-3';  P. malariae: 5'-GAGTGTTTCTTTTA-
Alignment of sequenced 18SrRNA gene Figure 1
Alignment of sequenced 18SrRNA gene. Forward primers used in the different assays are shown in italics. Beacon and 
reverse primers are shown in bold.
P. VIVAX: TCAGATACCGTCGTAATCTTAACCATAAACTATGCCGACTAGGCTTTGGATGAAAGATTTTAA
P. OVALE: TCAGATACCGTCGTAATCTTAACCATAAACTATGCCAACTATGTTTTGGATGTATGAGAAAAA
P. MALARIAE: TCAGATACCGTCGTAATCTTAACCATAAACTATGCCGACTAGGTGTTGGATGATAGAGTAAAA
P. VIVAX AATAAGA ATTTTCTCTTCGGAGTTTATTC .TTAGATT GCTTCCTTTAGTG
P. OVALE: GATGGAA TACTTTGTTTTACGACATTGTCATTCCATTTAC GCTTCATTCAGTA
P. MALARIAE: AATAAAA GAGACATTCATATATATGAGTGTTTCTT TTAGATA GCTTCCTTCAGTA
P. VIVAX: CCTTATGAGAAATCAAAGTCTTTG GGTTCTGGGGCGAGTATTCGCGCAAGCAGAAAGTT
P. OVALE: CCTTATGAGAAATCAAAGTCTTTG GGTTCTGGGGCGAGTATTCGCGCAAGCAGAAAGTT
P. MALARIAE: CCTTATGAGAAATCAAAGTCTTTG GGTTCTGGGGCGAGTATTCGCGCAAGCAGAAAGTTMalaria Journal 2006, 5:80 http://www.malariajournal.com/content/5/1/80
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GATAGC-3'. A T7 promotor sequence was added to the
generic  Plasmodium  NASBA reverse primer; 5'-
AATTCTAATACGACTCACTATAGGGAGAAGGAACTT-
TCTCGCTTGCGCGAA-3'. The published pf18S molecular
beacon 5'-6-carboxyfluorescein-CGATCGGAGAAAT-
CAAAGTCTTTGGGCGATCG-dimethylaminoazosulfonic
acid-3' was used as a detection probe [9].
The molecular work was performed under permit 02–080
granted on 22 February 2002 to KIT Biomedical Research
by the Netherlands Ministry for Spatial Planning, Housing
and the Environment.
Real-time – QT-NASBA
Real-time QT-NASBA for 18S rRNA of P. falciparum, P.
vivax, P. malariae and P. ovale was performed on an IQ5
Real-Time analyser (Bio-RAD). The reactions were per-
formed with the Nuclisens Basic kit for amplification
(BioMerieux) according to the manufacturers instructions
with a KCl concentration of 80 mM for P. falciparum, P.
vivax and P. malariae and 70 mM for P. ovale. The reaction
mixture (5 μl) containing the primers (100 pmol/μl)
molecular beacon (20 μM) and template RNA (2.5 μl) was
incubated at 65°C for two minutes followed by two min-
utes at 41°C. Thereafter, 2.5 μl enzyme mixture from the
basic kit was added to each reaction. Amplification was
monitored for 60 minutes after which the results were
analysed. A sample containing only water and reaction
mixture was used as blank and served as control for back-
ground fluorescence. The signal produced by the blank
samples is automatically subtracted from the analytical
samples (Bio-RAD IQ5 software v. 1.0). In order to quan-
tify the number of parasites in a clinical sample, a 10 fold
serial dilution of 109 to 102 molecules of in vitro RNA per
amplification reaction of each respective Plasmodium spe-
cies was run in triplicate in each test, wherein 104 mole-
cules corresponds to one Plasmodium parasite [10].
Clinical samples
Blood samples for validation (n = 79) were obtained from
patients diagnosed with malaria by detection and differ-
entiation of Plasmodium parasites in Giemsa-stained slides
with standard microscopy according to WHO recommen-
dations [11] or PCR methods as established in the con-
tributing medical centres. The samples were collected
from returned travellers with clinical symptoms visiting
the out patient clinic of the University Medical Centre Lei-
den (The Netherlands) and the Academic Medical Centre
Amsterdam (The Netherlands) and from ongoing field
studies in Vietnam, Turkey and Kenya (Table 1). The sam-
ples were tested blinded from the diagnostic results. Spe-
cificity of the assays was tested against in vitro RNA of the
four Plasmodium species and RNA isolated from Plasmo-
dium berghei isolates (12 samples). Furthermore 20 sam-
ples from Dutch healthy blood donors were tested as
negative controls. Blood samples (50 μl) were mixed with
950 μl guanidium isothiocyanate lysis buffer and RNA
was isolated as described previously [12].
Statistical analysis of test performance
Microscopy performed at initial diagnosis was considered
as the golden standard for this purpose and all NASBA
results were compared to these results. The agreement
between microscopy and the real-time QT-NASBA assay
was determined by calculating Kappa values with a 95%
confidence interval (Altman, 1991). Kappa values express
the agreement beyond chance and a kappa value of 0.21–
0.60 is a moderate, a kappa value of 0.61–0.80 a good and
kappa > 0.80 an almost perfect agreement beyond chance.
Results
Analytical performance of the assay
The lower detection limit of the developed assay as deter-
mined by analysing serial dilutions of in vitro RNA of P.
vivax, P. ovale or P. malariae, respectively, was 100 – 1,000
Table 1: Overview of sample origin
Species microscopy Origin of samples
P. falciparum 11 Kenya (KITa)
P. vivax 37 8 LUMCb, 24 Turkey (Izmirc), 5 Vietnam (KIT)
P. malariae 7 2 Kenya (KIT) 4 Kenya (Nijmegend)
P. ovale 4 3 LUMC 1 AMCe
Mixed infection 20 Kenya (Nijmegend)
P. berghei 12 LUMC (mouse isolate)
a. Royal Tropical Institute, Amsterdam, The Netherlands.
b. Leiden University Medical Centre, Leiden, The Netherlands.
c. Ege University Medical School, Izmir, Turkey.
d. Radboud University, Nijmegen, The Netherlands.
e. Academic Medical Centre, Amsterdam, The NetherlandsMalaria Journal 2006, 5:80 http://www.malariajournal.com/content/5/1/80
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molecules of in vitro RNA for each species, corresponding
to 0.1 – 0.01 parasite per diagnostic sample (i.e. 50 μl of
processed blood) (Figure 2, 3 and 4). No cross-hybridisa-
tion of the primers with the in vitro RNA of the other spe-
cies and none with P. berghei RNA isolated from mice (n =
12) was observed. Blood samples form healthy donors (n
= 20) showed no reaction in any of the assays.
Clinical performance of the assay
The developed real-time QT-NASBA was further evaluated
using 79 clinical samples (Table 2). Real-time QT-NASBA
confirmed the initial diagnosis with microscopy of 69 out
of the 79 clinical samples. The 37 P. vivax samples were
found to be P. vivax with microscopy as well as with
NASBA. However, one clinical sample gave an additional
weak P. ovale signal with the real-time QT-NASBA. The
four P. ovale samples were identified as such by real-time
QT-NASBA. However, one sample gave a weak additional
P. vivax signal. Two of the seven P. malariae mono-infec-
tions were found negative by NASBA. Furthermore, three
of the seven P. malariae mono-infections were identified
with real-time QT-NASBA as a P. falciparum/P. malariae
mixed infection. Only 11 P. falciparum samples were ana-
lysed with real-time QT-NASBA in the present study, as a
thorough analysis of this species has already been done
[9]. The microscopical diagnosis P. falciparum of the clin-
ical samples tested in the present study was confirmed by
NASBA. Of the 20 P. falciparum/P. malariae mixed infec-
tions, 19 were identified as a mixed infection with NASBA:
17 being a mixed infection of P. falciparum/P. malariae and
two samples gave a weak P. vivax reaction instead of P.
malariae. One sample was identified with real-time QT-
NASBA as a P. falciparum mono-infection.
Of the 10 discordant results, seven samples were re-ana-
lysed by re-reading the blood slides by an expert micro-
scopist who was blinded from the original microscopy
and NASBA results. There were no back-up slides or PCR
samples available from the other three discordant results.
The microscopic re-analysis resolved five discordant
results. In the three P. malariae mono-infections that were
identified as a mixed infection by real-time QT-NASBA, a
very low number of P. falciparum was found after re-read-
ing the slides. In the two slides which were initially diag-
nosed by microscopy as being P. falciparum/P. malariae
mixed infections, but with real-time QT-NASBA as being a
P. falciparum/P. vivax mixed infection, the results of re-
reading the blood slides were inconclusive for the pres-
ence of P. malariae and/or other Plasmodium species.
Standard curves of the P. ovale assay Figure 4
Standard curves of the P. ovale assay and figure c the 
standard curve of the NASBA assay with P. ovale in vitro 
RNA using the P. ovale specific forward and generic revere 
primer and beacon. R2 = 0,993.
Standard curves of the P. malariae assay Figure 2
Standard curves of the P. malariae assay. A standard 
curve of the NASBA assay with P. malariae in vitro RNA using 
the P. malariae specific forward and generic revere primer 
and beacon. R2 = 0,972.
Standard curves of the P. vivax assay Figure 3
Standard curves of the P. vivax assay. A standard curve 
of the NASBA assay with P. vivax in vitro RNA using the P. 
vivax specific forward and generic revere primer and beacon 
wit an R2 = 0,992.Malaria Journal 2006, 5:80 http://www.malariajournal.com/content/5/1/80
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Statistical analysis
A high degree of agreement was observed between the
real-time QT-NASBA assay and microscopy in the present
study. A kappa value of 0.926 (95% CI 0.872–0.967) indi-
cates a very good agreement beyond change.
Discussion
The aim of the present study was to develop a real-time
QT-NASBA for the detection of all four human Plasmo-
dium species. Based on the analytical evaluation of the
developed test, it was concluded that the sensitivity of the
developed tests is 0.1 to 0.01 parasites per diagnostic sam-
ple. This is comparable to the previously developed
NASBA for P. falciparum [9] and approximately 50 times
more sensitive than standard microscopy [2]. The devel-
oped molecular assays identified in 69 out of 79 samples
the same species as the initial microscopical diagnosis.
After re-checking the slides, the molecular diagnosis
appeared to be correct in three discordant cases, leaving
five results unresolved. The apparent discrepancy between
the two diagnostic tests may be due to a very low number
of parasites in the sample below the detection limit of
microscopy, but still detectable with real-time QT-NASBA.
The fact that in one sample no signal was obtained with
real-time QT-NASBA could be due to degradation of the
RNA or extraction failure. Unfortunately there was no
backup sample available to repeat the extraction and anal-
ysis. In principal, quantification of parasites is possible
with real-time QT-NASBA, but comparison with micro-
scopic data from the clinical samples was not possible
since parasite counts from the slides were not available. A
parasite in vitro culture was also not available for P. vivax,
P. ovale and P. malariae, making it difficult to make exact
calculations. The parasite calculations used in the present
study are based on the number of in vitro RNA molecules,
which correlates to the number P. falciparum parasites
[10]. It is assumed that these quantities are comparable to
the other species. In general there is little clinical relevance
for quantification of the P. ovale, P. malariae and P. vivax
since the patients normally have < 2% parasitaemia [13]
and treatment is given on basis of the infecting species
and not on parasitaemia. In contrast, the parasitaemia in
P. falciparum infection is an important factor for treatment
regimen and monitoring of treatment efficacy. It has been
shown that QT-NASBA is a valuable tool for assessing the
parasite dynamics in studies where drug efficacy is moni-
tored or drug combinations are compared [10,14]. The
submicroscopic detection limit of the NASBA technique
offers the possibility to monitor even small differences
that are otherwise not noticed by microscopy and may
even be a predictor for treatment failure [14].
Conclusion
The developed real-time QT-NASBA for the detection of
all four human Plasmodium species based on the 18S rRNA
gene of Plasmodium showed to be a very sensitive and spe-
cific technique with a detection limit of 0.1 parasites per
diagnostic sample. The assay can be used for the detec-
tion, identification and quantitative measurement of all
human  Plasmodium  species even at low parasite levels,
thus making it an effective tool for diagnostic purposes
and useful for epidemiological and drug studies.
Authors' contributions
PFM: Development and design of the NASBA assays, vali-
dation of the assay and molecular analysis of samples.
Analysis and interpretation of the data, drafting and pre-
paring the manuscript.
GJS: Cloning and expression of in vitro RNA, Sequencing
of Plasmodium templates and primer design and molecular
analysis.
PAK: Facilitating and coordination of the collection of
clinical samples. Interpretation of the data and critically
revising the manuscript.
HDFHS: Conception of the study and participation in its
design and coordination. Interpetation of the data, criti-
cally reading of the manuscript
All authors read and approved the final manuscript.
Table 2: Positive Plasmodium samples.
Species Microscopy NASBA Pf NASBA Pv NASBA Po NASBA Pm
P. falciparum 11 11 0 0 0
P. vivax 37 0 37 1 0
P. malariae 73 0 0 5
P. ovale 40 1 4 0
Mixed infection 20 20 2 0 17
P. berghei 12 0 0 0 0
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